Synta has a diverse pipeline of novel, small molecule drug candidates targeting
cancer and inflammatory diseases, two of the largest therapeutic markets in the
world.
Each program represents an independent drug category with a distinct chemical
family and mechanism of action. All clinical candidates were invented
internally by Synta scientists using our compound library and discovery
capabilities.
|
